Statin-associated pleiotropy: Possible beneficial effects beyond cholesterol reduction

Pharmacotherapy

Volumn 26, Issue 7 II, 2006, Pages

  Ito, Matthew K ^a   Talbert, Robert L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Dyslipidemia; HMG CoA; Pleiotropy cardiovascular risk; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERY ENDOTHELIUM; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PLEIOTROPY; VASCULITIS;

ATHEROSCLEROSIS; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; OXIDATIVE STRESS;

EID: 33745590135     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.7part2.85S     Document Type: Conference Paper

References (64)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
2. (Erratum in Circulation 2004;110:763.)
3. McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering benefits versus risks. Am J Cardiol 2005;96:E60-6.
4. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am 2000;84:23-42.
5. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-60.
6. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003;124:740-3.
7. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5.
8. Rizzo M, Di Fede G, Mansueto P, Castello F, Carmina E, Rini GB. Statins and osteoporosis: myth or reality? Minerva Med 2004;95:521-7.
9. Hoglund K, Thelen KM, Syversen S, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:256-65.
10. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-24.
11. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-7.
12. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med 2005;165:2007-12.
13. Van Denderen JC, Peters M, Halm VV, Horst-Bruinsma IV, Dijkmans B, Nurmohamed M. Statin therapy might be beneficial for treating patients with ankylosing spondylitis. Ann Rheum Dis 2005 Oct 11. (Epub ahead of print.)
14. Warnholtz A, Genth-Zotz S, Munzel T. Should treatment of sepsis include statins? Circulation 2005;111:1735-7.
15. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111:1841-6.
16. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study - a randomized controlled trial. JAMA 2001;285:1711-18.
17. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
18. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-8.
19. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-63.
20. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124-9.
21. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005;165:62-7.
22. Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the program on the surgical control of the hyperlipidemias (POSCH). J Am Coll Cardiol 1995;26:351-7.
23. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
24. Rifkind BM. Lipid research clinics coronary primary prevention trial: results and implications. Am J Cardiol 1984;54:C30-4.
25. The LRC-CPPT Group. Lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
26. Probstfield JL, Rifkind BM. The lipid research clinics coronary primary prevention trial: design, results, and implications. Eur J Clin Pharmacol 1991;40(suppl 1):S69-75.
27. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
28. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 1998;97:1440-5.
29. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001;103:357-62.
30. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation 2000;102:21-7.
31. Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005;26:2032-8.
32. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005;96:611-16.
33. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
34. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
35. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-6.
36. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
37. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1417-24.
38. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6.
39. Anonymous. Pravachol (pravastatin sodium). In: Physicians' desk reference, 60th ed. Montvale, NJ: Thomson PDR, 2006:943-8.
40. Anonymous. Lipitor (atorvastatin calcium). In: Physicians' desk reference, 60th ed. Montvale, NJ: Thomson PDR, 2006:2495-8.
41. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:F54-60.
42. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies-part 1. Circulation 2003;108:1664-72.
43. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies-part II. Circulation 2003;108:1772-8.
44. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
45. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000;10:195-203.
46. (Erratum in Nutr Metab Cardiovasc Dis 2001;11:111).
47. Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005;112:300-3.
48. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. 1. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105: 1387-93.
49. Schafer A, Fraccarollo D, Eigenthaler M, et al. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 2005;25:1071-7.
50. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112:93-102.
51. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-69.
52. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
53. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8.
54. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19.
55. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
56. Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000;30:473-80.
57. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-5.
58. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
59. Nishikawa H, Miura S, Zhang B, et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68:121-5.
60. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24.
61. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106:2118-24.
62. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-5.
63. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105: 868-73.
64. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 2004;109:97-102.